97 related articles for article (PubMed ID: 24555961)
41. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
42. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
Munroe M; Kolesar J
Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701
[TBL] [Abstract][Full Text] [Related]
43. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
44. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
45. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
46. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Carden CP; Yap TA; Kaye SB
Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
[TBL] [Abstract][Full Text] [Related]
47. Olaparib for the treatment of ovarian cancer.
Bornstein E; Jimeno A
Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
[TBL] [Abstract][Full Text] [Related]
48. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
49. Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
De Jaeghere E; Vandecasteele K; Claes K; Makar A; Tummers P; Cocquyt V; Denys H
Acta Clin Belg; 2017 Feb; 72(1):6-11. PubMed ID: 27267353
[TBL] [Abstract][Full Text] [Related]
50. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
51. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
52. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Kim G; Ison G; McKee AE; Zhang H; Tang S; Gwise T; Sridhara R; Lee E; Tzou A; Philip R; Chiu HJ; Ricks TK; Palmby T; Russell AM; Ladouceur G; Pfuma E; Li H; Zhao L; Liu Q; Venugopal R; Ibrahim A; Pazdur R
Clin Cancer Res; 2015 Oct; 21(19):4257-61. PubMed ID: 26187614
[TBL] [Abstract][Full Text] [Related]
53. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Lord CJ; Tutt AN; Ashworth A
Annu Rev Med; 2015; 66():455-70. PubMed ID: 25341009
[TBL] [Abstract][Full Text] [Related]
54. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
[TBL] [Abstract][Full Text] [Related]
55. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic approaches for women predisposed to breast cancer.
Nathanson KL; Domchek SM
Annu Rev Med; 2011; 62():295-306. PubMed ID: 21034216
[TBL] [Abstract][Full Text] [Related]
57. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Walsh CS
Gynecol Oncol; 2015 May; 137(2):343-50. PubMed ID: 25725131
[TBL] [Abstract][Full Text] [Related]
58. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Papadimitriou M; Mountzios G; Papadimitriou CA
Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
[TBL] [Abstract][Full Text] [Related]
59. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
Banerjee S; Kaye S
Curr Oncol Rep; 2011 Dec; 13(6):442-9. PubMed ID: 21913063
[TBL] [Abstract][Full Text] [Related]
60. Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.
LaFargue CJ; Tewari KS
Recent Pat Biotechnol; 2016; 9(2):86-101. PubMed ID: 26961668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
